|
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
|
2R42CA203456-02A1
|
$999,501
|
MARATHI, UPENDRA
|
7 HILLS PHARMA, LLC
|
|
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
|
2R44CA210817-02
|
$1,101,350
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
MOTILITY AND INVASION
|
5P01CA100324-16
|
$2,028,990
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Use of focused ultrasound to increase melanoma immunogenicity and inhibit tumor-induced T cell tolerance
|
1R01CA226861-01
|
$382,013
|
MACIAN, FERNANDO
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Dissecting Skp2 functions in pRb and p53 doubly deficient tumorigenesis
|
5R01CA201458-03
|
$382,013
|
ZHU, LIANG
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
A NOVEL SMALL MOLECULE CX3CR1 ANTAGONIST HALTS METASTASIS
|
5R44CA183362-03
|
$789,107
|
SALVINO, JOSEPH
|
ALLIANCE DISCOVERY, INC.
|
|
Synergistic Anti-tumor Efficacy of an Interleukin 2 Analog and PD-1 blockade
|
1R43CA228319-01
|
$299,794
|
CHEN, RIDONG
|
APT THERAPEUTICS, INC.
|
|
Role of SLC13A3 in Renal Cell Carcinoma
|
5F31CA210612-03
|
$29,664
|
JORDAN, ANDRE
|
AUGUSTA UNIVERSITY
|
|
Novel Biomarkers for the Clinical Management of Bladder Cancer
|
1R01CA227277-01A1
|
$466,211
|
LOKESHWAR, VINATA
|
AUGUSTA UNIVERSITY
|
|
Integration of Predictive Biomarkers of Hormone Resistance in Breast Cancer
|
5R01CA072038-20
|
$320,963
|
FUQUA, SUZANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Mitochondrial DNA copy number and fat metabolism in triple negative breast cancer
|
5R03CA212816-02
|
$79,250
|
KAIPPARETTU, BENNY
|
BAYLOR COLLEGE OF MEDICINE
|
|
Translational control of EMT by the CELF1 RNA Binding Protein
|
5R01CA190467-04
|
$362,569
|
NEILSON, JOEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
Wnt pathway dynamics in breast cancer metastasis
|
5K22CA207463-02
|
$188,042
|
ROARTY, KEVIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Osteoclast-independent mechanisms of early-stage bone colonization of breast canc
|
5R01CA183878-05
|
$324,738
|
ZHANG, XIANG
|
BAYLOR COLLEGE OF MEDICINE
|
|
MACROPHAGE-MEDIATED IMMUNOSURVEILLANCE IN CANCER
|
5R00CA201075-04
|
$248,912
|
FENG, MINGYE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A New Mechanism for Castration Resistant Prostate Cancer
|
5R01CA166894-06
|
$368,984
|
SUN, ZIJIE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Combating Resistance to Antiangiogenic Therapy in Renal Cell Carcinoma
|
5R01CA196996-04
|
$398,025
|
BHATT, RUPAL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
BRAFV600E and VEGFR2 synergize to trigger papillary thyroid cancer progression
|
5R01CA181183-05
|
$361,050
|
NUCERA, CARMELO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Characterizing the signaling pathways that regulate Skp2 oncogenic function
|
5R01CA200573-03
|
$395,738
|
WEI, WENYI
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Cancer Imaging and Therapy Analysis Platform (CITAP)
|
2R44CA213601-02
|
$817,362
|
GARGESHA, MADHUSUDHANA
|
BIOINVISION, INC.
|
|
PathMAP NSCLC: A functional companion diagnostic test to predict optimal therapy for patients with non-small cell lung cancer.
|
5R44CA203068-03
|
$993,966
|
BERTENSHAW, GREG
|
BIOMARKER STRATEGIES, LLC
|
|
Understanding the mechanisms of immune suppression in lymph node metastases
|
1K22CA230315-01
|
$200,880
|
JONES, DENNIS
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
PAX3 pathways in melanoma
|
5R01CA184001-05
|
$377,438
|
LANG, DEBORAH
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy
|
1U2CCA233238-01
|
$6,692,860
|
SPIRA, AVRUM
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Enzyme-instructed self-assembly for molecular anticancer nanomedicines
|
5R01CA142746-09
|
$368,145
|
XU, BING
|
BRANDEIS UNIVERSITY
|
|
Understanding How Breast Cancers Activate and Respond to the Systemic Environment
|
5R01CA166284-07
|
$148,621
|
MCALLISTER, SANDRA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Spatiotemporal delivery of synergistic drug combinations to kidney cancer
|
1R01CA229772-01
|
$360,930
|
SABBISETTI, VENKATA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Fate and efficacy of targeted therapies for metastatic tumors
|
5R01CA201148-04
|
$388,180
|
SHAH, KHALID
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
High Content Screening of Multicellular Invasion with 3D Traction Force Microscopy
|
5R21CA212932-02
|
$225,513
|
WONG, IAN
|
BROWN UNIVERSITY
|
|
Investigating Fatty Acid Oxidation in Primary and Metastatic MYC-Overexpressing Triple-Negative Breast Cancer
|
4K00CA212488-03
|
$73,386
|
CAMARDA, ROMAN
|
BUCK INSTITUTE FOR RESEARCH ON AGING
|
|
CapioCyte circulating tumor cell assay as a biomarker for cancer immunotherapy response
|
1R43CA232924-01
|
$209,801
|
MILLER, STEVEN
|
CAPIO BIOSCIENCES, INC.
|
|
Defining the role of endometrial cancer PP2A A-alpha mutations in tumorigenesis
|
1F30CA224979-01A1
|
$44,524
|
TAYLOR, SARAH
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Defining the Super-Enhancer Landscape in Triple Negative Breast Cancer Subtypes
|
5F31CA224809-02
|
$48,883
|
WEBB, BRYAN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
I- Corps Administrative Supplement to Novel Reagents for Breast Tumor SPECT Imaging R41CA217546
|
3R41CA217546-01S1
|
$50,000
|
LEVIN, MICHAEL
|
CAVATAR, LLC
|
|
Prostate Cancer Bone Metastasis Biology and Targeting
|
3P01CA098912-14S1
|
$18,678
|
CHUNG, LELAND
|
CEDARS-SINAI MEDICAL CENTER
|
|
Prostate Cancer Bone Metastasis Biology and Targeting
|
3P01CA098912-14S2
|
$12,477
|
CHUNG, LELAND
|
CEDARS-SINAI MEDICAL CENTER
|
|
The Role of FOXCI in Basal-like Breast Cancer
|
2R01CA151610-06
|
$415,527
|
CUI, XIAOJIANG
|
CEDARS-SINAI MEDICAL CENTER
|
|
Investigation and functional characterization of new drivers of mesenchymal tumorigenesis.
|
4R00CA212200-03
|
$249,000
|
GUARNERIO, JLENIA
|
CEDARS-SINAI MEDICAL CENTER
|
|
Corrole nanobiologics for targeting resistant and metastatic tumors
|
5R01CA140995-08
|
$415,625
|
MEDINA-KAUWE, LALI
|
CEDARS-SINAI MEDICAL CENTER
|
|
Cancer-Associated Fibroblasts Alter the Composition of B Cells I Solid Malignancies - Diversity Supplement
|
3R01CA208753-03S1
|
$106,651
|
ORSULIC, SANDRA
|
CEDARS-SINAI MEDICAL CENTER
|
|
Cancer-Associated Fibroblasts Alter the Composition of B cells in Solid Malignancies
|
5R01CA208753-03
|
$400,313
|
ORSULIC, SANDRA
|
CEDARS-SINAI MEDICAL CENTER
|
|
A blood test to identify prostate cancer patients at risk for visceral metastasis
|
5R01CA218356-02
|
$601,750
|
POSADAS, EDWIN
|
CEDARS-SINAI MEDICAL CENTER
|
|
Understanding the AGL metastasis suppressor for therapeutic gain
|
3R01CA143971-08S1
|
$149,644
|
THEODORESCU, DAN
|
CEDARS-SINAI MEDICAL CENTER
|
|
Regulation and Targeting of CD24 in Bladder Cancer
|
7R01CA075115-20
|
$357,944
|
THEODORESCU, DAN
|
CEDARS-SINAI MEDICAL CENTER
|
|
Understanding the AGL metastasis suppressor for therapeutic gain
|
7R01CA143971-08
|
$481,438
|
THEODORESCU, DAN
|
CEDARS-SINAI MEDICAL CENTER
|
|
Specificity and safety of a targeted therapy against triple negative breast cancer
|
1R43CA224750-01A1
|
$300,000
|
IVANOVSKA, IRENA
|
CELDARA MEDICAL, LLC
|
|
Targeted Inhibition in Triple Negative Breast Cancer
|
1R21CA229930-01
|
$172,913
|
NASSAR, NICOLAS
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
Compensatory steroidogenesis mechanisms in castration-resistant prostate cancer
|
3R01CA190289-04S1
|
$89,498
|
SHARIFI, NIMA
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
CSHL Cancer Gene Discovery and Cancer Biology Postdoctoral Research Training Program
|
5T32CA148056-08
|
$146,168
|
MILLS, ALEA
|
COLD SPRING HARBOR LABORATORY
|
|
CSHL 2018 Mechanisms and Models of Cancer
|
1R13CA228219-01
|
$10,000
|
STEWART, DAVID
|
COLD SPRING HARBOR LABORATORY
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|